Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 7Colonic Neoplasms 2Stomach Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1

Interventions

Oxaliplatin 13Bevacizumab 11Capecitabine 10Fluorouracil 8Blood Specimen Collection 8Leucovorin 7Cetuximab 7Folfox protocol 6pembrolizumab 5Drug Therapy 5trifluridine tipiracil drug combination 4dostarlimab 4Nivolumab 4Irinotecan 4HMPL-013 4fludarabine 3XELOX 3Specimen Handling 3IFL protocol 3Cyclophosphamide 3Biopsy 3toripalimab 2tislelizumab 2tipiracil 2regorafenib 2pertuzumab 2envafolimab 2encorafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Colonic Neoplasms × tipiracil × Clear all
NCT04920032 2026-05-11

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

University of California, Irvine

Phase 1 Recruiting
22 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Ruijin Hospital

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡